Lori Prok
Concepts (107)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 5 | 2022 | 762 | 0.560 |
Why?
| Nails | 1 | 2015 | 10 | 0.550 |
Why?
| Hair Diseases | 1 | 2015 | 6 | 0.540 |
Why?
| Facial Dermatoses | 1 | 2015 | 14 | 0.540 |
Why?
| Thumb | 1 | 2015 | 23 | 0.540 |
Why?
| Video Games | 1 | 2015 | 22 | 0.540 |
Why?
| Cumulative Trauma Disorders | 1 | 2015 | 30 | 0.530 |
Why?
| Polyomavirus Infections | 1 | 2015 | 22 | 0.530 |
Why?
| Hair Follicle | 1 | 2015 | 52 | 0.530 |
Why?
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 65 | 0.500 |
Why?
| Immunocompromised Host | 1 | 2015 | 200 | 0.470 |
Why?
| Pemphigoid, Bullous | 1 | 2013 | 7 | 0.450 |
Why?
| Antimutagenic Agents | 1 | 2012 | 1 | 0.450 |
Why?
| Tattooing | 1 | 2012 | 10 | 0.440 |
Why?
| Polymethyl Methacrylate | 1 | 2012 | 20 | 0.440 |
Why?
| Drug Eruptions | 1 | 2012 | 26 | 0.440 |
Why?
| Xanthomatosis | 1 | 2010 | 11 | 0.370 |
Why?
| Hyperlipidemias | 1 | 2010 | 128 | 0.340 |
Why?
| Nevus | 1 | 2007 | 25 | 0.290 |
Why?
| Dermatology | 2 | 2022 | 88 | 0.280 |
Why?
| Hemangioma | 2 | 2016 | 41 | 0.260 |
Why?
| Adrenergic alpha-Agonists | 1 | 2003 | 31 | 0.230 |
Why?
| Muscle Hypotonia | 1 | 2003 | 31 | 0.230 |
Why?
| Apnea | 1 | 2003 | 16 | 0.230 |
Why?
| Sleep Stages | 1 | 2003 | 60 | 0.220 |
Why?
| Quinoxalines | 1 | 2003 | 62 | 0.220 |
Why?
| Myofibroma | 1 | 2022 | 4 | 0.210 |
Why?
| Myofibromatosis | 1 | 2022 | 6 | 0.210 |
Why?
| Acne Vulgaris | 1 | 2022 | 20 | 0.210 |
Why?
| Soft Tissue Neoplasms | 1 | 2022 | 93 | 0.200 |
Why?
| Skin | 3 | 2018 | 657 | 0.190 |
Why?
| Mycosis Fungoides | 1 | 2018 | 62 | 0.160 |
Why?
| Diagnosis, Differential | 3 | 2018 | 1384 | 0.150 |
Why?
| Stevens-Johnson Syndrome | 1 | 2017 | 34 | 0.150 |
Why?
| GTP-Binding Protein alpha Subunits | 1 | 2016 | 13 | 0.150 |
Why?
| Child | 7 | 2022 | 19129 | 0.150 |
Why?
| Neoplasms, Multiple Primary | 1 | 2016 | 56 | 0.140 |
Why?
| Histiocytosis | 1 | 2015 | 8 | 0.140 |
Why?
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 24 | 0.130 |
Why?
| Cytosine | 1 | 2015 | 46 | 0.130 |
Why?
| Organophosphonates | 1 | 2015 | 94 | 0.130 |
Why?
| Rare Diseases | 1 | 2015 | 113 | 0.130 |
Why?
| Endothelium, Lymphatic | 1 | 2014 | 12 | 0.120 |
Why?
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2014 | 22 | 0.120 |
Why?
| Hydrops Fetalis | 1 | 2014 | 14 | 0.120 |
Why?
| Lymphatic Abnormalities | 1 | 2014 | 18 | 0.120 |
Why?
| Humans | 17 | 2022 | 118974 | 0.120 |
Why?
| Telemedicine | 1 | 2022 | 664 | 0.120 |
Why?
| Blister | 1 | 2013 | 39 | 0.110 |
Why?
| Prednisolone | 1 | 2013 | 76 | 0.110 |
Why?
| Biopsy, Needle | 1 | 2013 | 190 | 0.110 |
Why?
| Coronary Artery Disease | 1 | 2018 | 647 | 0.110 |
Why?
| Immunohistochemistry | 2 | 2014 | 1691 | 0.100 |
Why?
| Male | 9 | 2018 | 57801 | 0.100 |
Why?
| Muscle, Smooth, Vascular | 1 | 2014 | 454 | 0.100 |
Why?
| Histiocytes | 1 | 2010 | 5 | 0.090 |
Why?
| Antiviral Agents | 1 | 2015 | 654 | 0.090 |
Why?
| Brain Neoplasms | 1 | 2018 | 1022 | 0.090 |
Why?
| Child, Preschool | 4 | 2017 | 9491 | 0.080 |
Why?
| Information Dissemination | 1 | 2010 | 210 | 0.080 |
Why?
| Cholesterol | 1 | 2010 | 373 | 0.080 |
Why?
| Triglycerides | 1 | 2010 | 519 | 0.080 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1390 | 0.080 |
Why?
| Internet | 1 | 2010 | 633 | 0.070 |
Why?
| Biopsy | 1 | 2010 | 1079 | 0.070 |
Why?
| Patient Education as Topic | 1 | 2010 | 699 | 0.070 |
Why?
| Disease Progression | 1 | 2013 | 2490 | 0.070 |
Why?
| Fatal Outcome | 2 | 2018 | 287 | 0.070 |
Why?
| Follow-Up Studies | 1 | 2013 | 4596 | 0.060 |
Why?
| Brimonidine Tartrate | 1 | 2003 | 9 | 0.060 |
Why?
| Risk Assessment | 1 | 2013 | 3057 | 0.060 |
Why?
| Infant, Newborn | 3 | 2016 | 5255 | 0.060 |
Why?
| Isotretinoin | 1 | 2022 | 22 | 0.050 |
Why?
| Emergency Service, Hospital | 1 | 2013 | 1865 | 0.050 |
Why?
| Internship and Residency | 1 | 2010 | 1001 | 0.050 |
Why?
| Infant | 3 | 2022 | 8293 | 0.050 |
Why?
| Cataract | 1 | 2003 | 194 | 0.050 |
Why?
| Melanoma | 1 | 2007 | 664 | 0.050 |
Why?
| Bone and Bones | 1 | 2022 | 289 | 0.040 |
Why?
| Treatment Outcome | 1 | 2013 | 9342 | 0.040 |
Why?
| Infliximab | 1 | 2018 | 94 | 0.040 |
Why?
| Mycoplasma Infections | 1 | 2017 | 12 | 0.040 |
Why?
| Chlamydophila pneumoniae | 1 | 2017 | 11 | 0.040 |
Why?
| Patient Satisfaction | 1 | 2022 | 610 | 0.040 |
Why?
| Mycoplasma pneumoniae | 1 | 2017 | 33 | 0.040 |
Why?
| Immunoglobulins, Intravenous | 1 | 2018 | 128 | 0.040 |
Why?
| Mouth Mucosa | 1 | 2017 | 82 | 0.040 |
Why?
| Female | 3 | 2014 | 61565 | 0.040 |
Why?
| Disseminated Intravascular Coagulation | 1 | 2016 | 30 | 0.040 |
Why?
| Coronary Vessels | 1 | 2018 | 233 | 0.040 |
Why?
| Antirheumatic Agents | 1 | 2018 | 254 | 0.030 |
Why?
| Echocardiography | 1 | 2018 | 556 | 0.030 |
Why?
| Aspirin | 1 | 2018 | 334 | 0.030 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 304 | 0.030 |
Why?
| Anemia | 1 | 2016 | 146 | 0.030 |
Why?
| Thrombocytopenia | 1 | 2016 | 185 | 0.030 |
Why?
| Antigens, CD34 | 1 | 2014 | 98 | 0.030 |
Why?
| Prenatal Diagnosis | 1 | 2014 | 168 | 0.030 |
Why?
| Actins | 1 | 2014 | 404 | 0.030 |
Why?
| Adult | 1 | 2012 | 31512 | 0.020 |
Why?
| Prospective Studies | 1 | 2022 | 6471 | 0.020 |
Why?
| Endothelium, Vascular | 1 | 2014 | 907 | 0.020 |
Why?
| Adolescent | 2 | 2017 | 18480 | 0.020 |
Why?
| Inflammation | 1 | 2017 | 2566 | 0.020 |
Why?
| Mutation | 1 | 2016 | 3457 | 0.020 |
Why?
| Pregnancy | 1 | 2014 | 5691 | 0.010 |
Why?
| Middle Aged | 1 | 2018 | 27617 | 0.010 |
Why?
|
|
Prok's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|